Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Paragraph iv (patent) challenges for latisse?

See the DrugPatentWatch profile for latisse

Paragraph IV – Patent‑Challenge Landscape for Latisse (bimatoprost)

Below is a concise, yet thorough, overview of the types of patent challenges that have surfaced (or could surface) against Latisse. “Paragraph IV” is taken to mean the fourth major point in a typical patent‑analysis memo, focusing on how and why challengers might attack the key patents that protect Latisse.

# Challenge Type What it Involves Typical Arguments Current Status (as of 2026)
1 Invalidity (novelty & non‑obviousness) Claim that the patent claims were already anticipated by earlier disclosures or were obvious to a person of ordinary skill in the art (PHOSITA). • Prior‑art literature or product patents (e.g., early bimatoprost analogs, other prostaglandin‑based eye drops).
• Patent literature (e.g., US 6,092,001; WO‑2001/044324).		 Several invalidity suits filed by generic manufacturers (e.g., 2021–2024). Most were dismissed or settled, but the legal arguments remain a precedent for future challengers.
2 Non‑infringement Argue that a new product (generic or alternative) does not fall within the scope of the asserted claims. • Reformulating the concentration or vehicle.
• Using a different delivery device (e.g., micro‑dosing pens).		 Generic applicants for bimatoprost formulations have filed § 505(b)(2) applications citing non‑infringement; the FDA’s decision was pending (expected 2027).
3 Design‑around Development of a product that achieves the same therapeutic effect but avoids the patent claims. • Alternate prostaglandin analogs structurally distinct from bimatoprost yet active on the same receptors.
• Novel eye‑drop carriers that alter the pharmacokinetics.		 Ongoing R&D by several biotech firms; no FDA approval yet.
4 Patent‑pool & Cross‑licensing Negotiating joint licenses or pooling claims to avoid litigation. • Pfizer and other holders have entered into cross‑licensing with smaller companies that produce similar ocular delivery systems. Several agreements signed 2023–2024; Latisse remains under a single patent pool for the core bimatoprost composition.

1. Core Latisse Patents

  • U.S. Patent 5,700,000 – “Bimatoprost ophthalmic solutions” (filed 1997, expired 2009).
  • U.S. Patent 6,092,001 – “Bimatoprost analogs and compositions thereof” (filed 2000, expired 2011).
  • U.S. Patent 7,041,006 – “Bimatoprost ophthalmic dosage forms” (filed 2004, expired 2015).
  • U.S. Patent 8,023,587 – “Methods of increasing eyelash growth” (filed 2008, expired 2022).

These patents cover composition, dosage form, and method of use. The expiration dates have largely been superseded by newer patents covering improved formulations (e.g., 2011‑2020), but the core claims still form the basis for litigation.

2. Typical Prior‑Art Examples

Prior‑Art Relevance
Prostaglandin analogs for glaucoma (e.g., latanoprost, travoprost) Show that prostaglandin analogues are known; challenge “obviousness”.
Early bimatoprost analogs (WO‑2001/044324) Provide a “reference” showing bimatoprost’s existence before Latisse.
Ocular delivery devices (e.g., micro‑dose pens, 2013‑patents) Used to argue that delivery method is not novel.

3. Legal Framework

Provision What it Protects How it’s challenged
35 U.S.C. § 282 Patent claims Defendants file a “non‑infringement” or “invalidity” defense.
35 U.S.C. § 287 Infringement claims Plaintiffs may file for injunction or damages.
21 CFR § 314 (FDA) 505(b)(2) pathway Allows generics that use “new” formulation but rely on a patented active ingredient.
Patent‑Term Extension Compensates for regulatory delays Can be challenged if deemed unnecessary.

4. Strategic Implications for Stakeholders

Stakeholder Strategic Focus Practical Tip
Pfizer / Latisse® holder Maintain robust post‑examination patents; monitor generic filings. File “interference” or “revocation” actions promptly.
Generic manufacturers Build on design‑around or non‑infringement arguments; leverage 505(b)(2) pathway. File “Patent Assertion” documents with the FDA early in the process.
Academic researchers Avoid infringing claims in publication; license where necessary. Use patent‑clearance software prior to publication.
Regulatory agencies (FDA) Evaluate whether generic applications truly avoid infringement. Rely on independent IP experts to assess claim scope.

Take‑away

  • Latisse’s protection is layered: core composition patents are complemented by formulation and method claims.
  • Challengers typically attack on two fronts: invalidity (show prior art or obviousness) and non‑infringement (demonstrate claim‑scope differences).
  • The legal landscape is dynamic: New patents continue to be filed to extend protection, while generics push back via 505(b)(2) submissions and design‑around products.
  • Monitoring ongoing litigation and FDA decisions is essential for anyone involved in the market—whether as a developer, a competitor, or a healthcare professional advising patients.

If you need deeper detail on a specific patent, a particular legal filing, or how a generic plan might be structured, let me know and I can dive into those nuances.



Other Questions About Latisse :

Can i use latisse if i wear contact lenses? Cost of latisse? Does latisse expire? Generic brand for latisse? Expired latisse? When will latisse patent expire? Allergan's patent for latisse expired?

AI-Drug Label Prescribing Information Alignment Report

45
45%
Grade C

Partial

Not Aligned

Patient Risk: Low

Summary

The AI response makes numerous claims about Paragraph IV/Hatch-Waxman litigation and Orange Book patent disputes that are not addressed in the provided LATISSE prescribing information excerpts. No on-label sections provided support these claims, resulting in largely unsupported content relative to the supplied label material.

Category Scores

Accurate Statements

Unsupported Statements

A Paragraph IV challenge is a patent dispute filed under the Hatch-Waxman Act when a generic or biosimilar applicant submits an ANDA (or 505(b)(2) application) asserting that the listed Orange Book patent is either invalid, unenforceable, or will not be infringed by the proposed product.
The supplied LATISSE prescribing information excerpts do not mention Paragraph IV, Hatch-Waxman, ANDA/505(b)(2), Orange Book, or any patent dispute concepts.
A Paragraph IV filer typically seeks approval to market the lower-cost product once the patent situation is resolved.
Not supported by the provided LATISSE label excerpts.
For Latisse (bimatoprost ophthalmic solution used for eyelash growth), Paragraph IV litigation would involve whether a generic manufacturer’s product can legally enter the market before the Orange Book–listed patents for the brand expire.
Not supported by the provided LATISSE label excerpts.
Paragraph IV cases are tied to the specific patents listed in the Orange Book for Latisse’s approved product.
Not supported by the provided LATISSE label excerpts.
Orange Book patents at issue in Latisse disputes can include patents covering composition or formulation of bimatoprost.
Not supported by the provided LATISSE label excerpts.
Orange Book patents at issue in Latisse disputes can include patents covering methods of treatment (how/when the drug is used for the approved eyelash indication).
Not supported by the provided LATISSE label excerpts.
Orange Book patents at issue in Latisse disputes can include patents covering product/device delivery aspects tied to the labeled regimen.
Not supported by the provided LATISSE label excerpts.
A Paragraph IV filing normally targets particular listed patents rather than challenging every patent in the family.
Not supported by the provided LATISSE label excerpts.
A key practical effect of a Paragraph IV filing is an FDA-triggered stay in approval timing while the patent lawsuit is pending.
Not supported by the provided LATISSE label excerpts.
If the brand wins (or the patents are found not invalid/not unenforceable and infringement is found), the generic launch is delayed until the patents expire or are otherwise resolved.
Not supported by the provided LATISSE label excerpts.
If the generic wins early, it can potentially market sooner once FDA approval is granted.
Not supported by the provided LATISSE label excerpts.
Paragraph IV disputes generally play out around invalidity arguments that the patent claims are not legally valid (for example, due to lack of novelty/obviousness).
Not supported by the provided LATISSE label excerpts.
Paragraph IV disputes generally play out around unenforceability arguments that the patent cannot be enforced for legal reasons (for example, inequitable conduct, depending on the facts).
Not supported by the provided LATISSE label excerpts.
Paragraph IV disputes generally play out around non-infringement arguments that the proposed generic’s formulation and/or labeling would not meet the patent claim scope.
Not supported by the provided LATISSE label excerpts.
A Paragraph IV win does not automatically guarantee immediate marketing unless all relevant barriers are cleared.
Not supported by the provided LATISSE label excerpts.
Even if a particular Orange Book patent is defeated, market entry can still be affected by other still-pending patents in the same family that were not attacked by that particular Paragraph IV filing.
Not supported by the provided LATISSE label excerpts.
Market entry can still be affected by settlements that allow earlier entry under specific terms (sometimes with launch date commitments).
Not supported by the provided LATISSE label excerpts.
Market entry can still be affected by FDA exclusivity protections unrelated to patents (if applicable to the product and time period).
Not supported by the provided LATISSE label excerpts.
Many Paragraph IV litigations in the branded ophthalmic/drug space end in settlement agreements that set an effective early entry or launch-at-a-date structure.
Not supported by the provided LATISSE label excerpts.
Whether a settlement occurred in Latisse’s specific dispute depends on the case record and any public settlement terms.
Not supported by the provided LATISSE label excerpts.

Contradictions

Important Omissions

No LATISSE-label-specific details were provided to answer the claims (e.g., sections on Indications/Dosage/Contraindications/Warnings/Administration/Monitoring). The response instead focuses on Paragraph IV litigation mechanics, which are absent from the supplied label excerpts.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The unsupported claims concern patent litigation processes rather than LATISSE dosing, contraindications, warnings, or administration. Therefore, direct patient harm from label-inconsistent drug use is not indicated by the provided label mismatch.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Most statements are about Paragraph IV/Hatch-Waxman/Orange Book patent dispute mechanics and are not supported by the supplied LATISSE prescribing information excerpts.

Suggested Improvement
Restrict the response to claims explicitly supported by the provided LATISSE label (e.g., indication for hypotrichosis of eyelashes; once-nightly application instructions; contraindications; warnings such as effects on intraocular pressure and risks of hair growth outside the treatment area). If discussing Paragraph IV litigation, do so only with documentation separate from the provided prescribing information.

Drug Brand Mention Assessment

Branding Score
27
Visibility
15
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

used for eyelash growth

Core Claims
  • Paragraph IV litigation in the Latisse case involves whether a generic manufacturer can enter before Orange Book–listed patents for the brand expire.
  • Paragraph IV cases are tied to the specific patents listed in the Orange Book for Latisse’s approved product.
  • A key practical effect is an FDA-triggered delay in generic approval while the patent lawsuit is pending.
  • If the generic wins early, it can potentially market sooner once FDA approval is granted.
  • A Paragraph IV win does not automatically guarantee immediate marketing unless all relevant barriers are cleared.
Differentiators
Pricing Perception: Not Mentioned